An IGF-1 result is only useful when read against the laboratory's age- and sex-specific range. Puberty, energy intake, liver function, pregnancy, medicines and assay method can shift the number before a growth hormone disorder is likely.
- Age-specific range: IGF-1 rises sharply during puberty and usually declines gradually after the third decade, so one adult cutoff is misleading.
- Z-score: A result expressed as a standard deviation score below -2.0 or above +2.0 is often more clinically useful than a raw ng/mL value.
- High result: IGF-1 above the assay-adjusted upper limit should be repeated and, if persistent, assessed for acromegaly or uncommon medication-related causes.
- Low result: Low IGF-1 can reflect undernutrition, liver disease, poorly controlled diabetes, oral estrogen or systemic illness—not only low growth hormone.
- Puberty effect: Tanner stage can move IGF-1 by several hundred ng/mL within 12 to 24 months in an otherwise well teenager.
- Pregnancy effect: Placental growth hormone changes maternal IGF-1 later in pregnancy, making non-pregnant adult ranges unreliable.
- Assay effect: Results from different laboratories can differ materially because IGF-binding proteins, calibration standards and analytic platforms vary.
- Next step: A single abnormal IGF-1 does not diagnose growth hormone deficiency or acromegaly; symptoms, growth pattern, repeat testing and specialist-led dynamic tests matter.
What an IGF-1 result actually tells you
IGF-1 is an integrated marker of growth hormone activity over days to weeks, not a direct measure of growth hormone secretion. A high or low result should first be compared with the reporting laboratory's age- and sex-adjusted interval, then interpreted alongside nutrition, liver tests, glucose status, medicines and symptoms.
Growth hormone arrives in pulses, especially overnight, whereas insulin-like growth factor 1 (IGF-1) is more stable in circulation. That stability is why clinicians commonly start with IGF-1 rather than a random growth hormone value, which may be undetectable in a healthy person sampled between pulses.
Kantesti is an AI blood test analyzer that reads an IGF-1 result beside the laboratory interval, age, sex and related markers rather than treating a red flag as a diagnosis. In my work as Thomas Klein, MD, the most preventable mistake is calling an isolated low value “growth hormone deficiency” before checking whether the person was ill, restricting food or taking oral estrogen.
IGF-1 is produced mainly by the liver after growth hormone signaling, but bone, muscle and other tissues also make it locally. A normal IGF-1 makes severe growth hormone excess less likely, yet symptoms still matter; our biomarker reference guide explains why a reference flag is a starting point, not a verdict.
Why one result can mislead
A result near a laboratory boundary can move across it without a biological change, particularly when the next sample is run on another assay. For a borderline finding, I usually want the same laboratory, the same method and a clinically stable period before attaching much meaning to a change smaller than about 20%.
How growth hormone, liver signaling and IGF-1 connect
The pituitary releases growth hormone, and the liver responds by making much of the IGF-1 measured in serum. This explains why pituitary disorders, liver impairment, insulin deficiency and severe calorie restriction can all produce a low IGF-1 pattern.
The hormone pathway is not a straight line. Growth hormone receptor function, liver protein synthesis, insulin availability and IGF-binding proteins all influence how much measurable IGF-1 reaches the laboratory sample; a low level can therefore arise even when the pituitary is capable of releasing growth hormone.
About 75% to 80% of circulating IGF-1 is carried in a ternary complex with IGF-binding protein-3 and acid-labile subunit. Severe liver dysfunction can lower both IGF-1 and IGFBP-3, which is one reason a low result in a person with jaundice, ascites or low albumin should not be used alone to diagnose pituitary disease.
Aging research sometimes treats IGF-1 as a simple longevity score, but the relationship is not that tidy. Before acting on a result obtained through a longevity panel, review the limits described in our IGF-1 and aging marker guide; pushing a normal result higher has no established health benefit.
The difference between circulating and tissue IGF-1
A serum IGF-1 test cannot measure local IGF-1 action inside muscle, cartilage or bone. That distinction helps explain why two people with similar values can have very different body composition, fracture risk or exercise response.
IGF-1 levels by age, sex and pubertal stage
IGF-1 levels are lowest in early childhood, peak during puberty, then decline progressively through adult life. A 14-year-old with 450 ng/mL may be entirely within range, while the same value in a 65-year-old would generally need confirmation and endocrine review.
The table gives broad illustrative intervals in ng/mL, not universal decision limits; the number printed beside your own result wins. Many laboratories publish separate male and female intervals in adolescence because peak timing differs by roughly 1 to 2 years, and Tanner stage is often more informative than chronological age alone.
During peak puberty, healthy IGF-1 values can be two to four times typical later-adult values. A growth spurt, voice change, breast development or changing menstrual pattern can therefore explain a startling-looking value better than a disease label; our teenage laboratory range guide puts this broader shift in context.
Assay-specific standard deviation scores, often called IGF-1 SDS or z-scores, account for age and sex. A z-score below -2.0 or above +2.0 is commonly used as a prompt for clinical assessment, although Clemmons et al. (2011) stressed that harmonisation between assays remains incomplete.
IGF-1 high meaning: when an elevated value matters
Persistently elevated IGF-1 above the assay-adjusted upper limit is the best screening clue for acromegaly, but it is not diagnostic by itself. The concern rises when it accompanies larger hands or shoe size, widening tooth gaps, headaches, sweating, sleep apnea, diabetes or difficult-to-control blood pressure.
Acromegaly usually results from excess growth hormone secretion by a pituitary adenoma, but changes develop slowly and can be missed for years. The Endocrine Society guideline recommends age-normalized IGF-1 as the initial test and confirmation with failure of growth hormone suppression during a 75-g oral glucose tolerance test when clinical suspicion remains high (Katznelson et al., 2014).
An IGF-1 result only 5% to 15% above the upper limit, without matching symptoms, is often repeated before imaging is considered. Pubertal timing, pregnancy, assay interference and a mismatched reference interval can explain a modest elevation; high IGF-1 does not automatically mean cancer, and it should not trigger a self-directed “anti-IGF” supplement regimen.
At Kantesti, we flag a high IGF-1 more strongly when related markers and symptoms point in the same direction rather than using a single-number alarm. A clinician may also check prolactin because mixed pituitary hormone secretion can occur; see our guide to prolactin symptoms and pituitary clues.
Low IGF-1 causes beyond growth hormone deficiency
Low IGF-1 most often reflects reduced hepatic production, low energy availability, chronic illness or poorly controlled diabetes before it proves growth hormone deficiency. The lower the value is below the age-adjusted range, the more useful it becomes—but the clinical setting still decides what happens next.
Adults with cirrhosis, active hepatitis, malabsorption, anorexia nervosa or prolonged fasting may have low IGF-1 despite intact pituitary signaling. A low albumin, raised bilirubin, prolonged INR or abnormal transaminases shifts attention toward hepatic synthesis; start with a liver panel explanation rather than assuming a hormone disorder.
Insulin supports hepatic IGF-1 production, so uncontrolled type 1 diabetes can cause a low result alongside high glucose and weight loss. In patients with substantial inflammation or kidney disease, altered binding proteins complicate interpretation further, and repeating the test after the acute problem settles is often more informative than testing growth hormone immediately.
Iron deficiency is not a direct, proven cause of low IGF-1 in every adult, but severe dietary restriction often combines low ferritin, low energy intake and low IGF-1. A complete iron studies interpretation can uncover that broader pattern, especially when fatigue and reduced exercise recovery coexist.
Nutrition, fasting and athletic training effects
Calorie deficit and low protein intake can reduce IGF-1 within days to weeks, even in fit people with no pituitary disease. The key clue is often a mismatch: low IGF-1 with recent weight loss, low libido, menstrual disruption, recurrent injury or declining training performance.
Short-term fasting lowers insulin and hepatic growth hormone responsiveness, creating a state sometimes described as growth hormone resistance: growth hormone may rise while IGF-1 falls. This is adaptive physiology, not evidence that a person should take growth hormone, and the result may improve after several weeks of stable intake.
In endurance athletes, persistent energy availability below roughly 30 kcal per kilogram of fat-free mass per day is associated with relative energy deficiency in sport risk, though a laboratory value cannot diagnose RED-S by itself. Our endurance athlete testing guide outlines the useful companion markers: ferritin, CBC indices, thyroid tests, vitamin D and reproductive-hormone context.
Protein intake matters, but more protein does not reliably raise IGF-1 above your physiologic set point. Most active adults do well with 1.2 to 1.6 g/kg/day during training, while people with kidney disease need individualized advice; our protein needs by age guide explains how to avoid reading one hormone in isolation.
Liver, kidney, thyroid and glucose conditions that shift IGF-1
Liver disease is one of the strongest non-pituitary causes of low IGF-1 because the liver makes most circulating IGF-1. Kidney impairment can alter clearance and binding proteins, while untreated hypothyroidism and uncontrolled diabetes can lower effective growth hormone signaling.
A low IGF-1 with low albumin and elevated bilirubin is more consistent with impaired liver synthetic function than isolated adult growth hormone deficiency. Conversely, a normal ALT does not rule out meaningful liver impairment, so I look at albumin, INR, bilirubin, platelets and clinical history together; our GGT range guide adds one useful liver-context marker.
Chronic kidney disease can increase measured growth hormone while reducing tissue responsiveness, and IGF-binding proteins may accumulate. That means a normal or low-normal IGF-1 in advanced kidney disease does not neatly exclude altered growth hormone physiology; eGFR and urine albumin deserve equal attention.
Kantesti is an AI lab test interpretation service that can identify when IGF-1, glucose, liver markers and renal function form a coherent pattern requiring medical review. The practical question is not “how do I normalize IGF-1?” but “which organ system explains this result?”
Pregnancy, estrogen and hormonal medicines
Pregnancy changes maternal IGF-1 physiology, particularly after mid-pregnancy when placental growth hormone increases liver IGF-1 production. Non-pregnant adult reference intervals are therefore unsuitable for judging a pregnant person's result unless the laboratory provides trimester-specific limits.
Maternal IGF-1 often falls early in pregnancy and rises later, but the magnitude varies with placental function, body composition and assay. A value that would look high outside pregnancy may be physiologic in the third trimester; pregnancy symptoms such as new severe headache, visual change or high blood pressure still need prompt obstetric assessment, regardless of IGF-1.
Oral estrogen can reduce liver production of IGF-1 and may blunt growth hormone treatment response, while transdermal estrogen has less hepatic first-pass effect. This distinction matters for people using combined oral contraception, menopausal hormone therapy or gender-affirming treatment; do not stop prescribed hormones simply to “fix” a laboratory number.
I have seen pregnancy panels generate needless anxiety when a test was ordered without a pregnancy-specific clinical question. For safe interpretation of accompanying abnormalities, use our pregnancy blood test red-flag guide and contact the maternity team rather than relying on an internet range.
Why laboratory method and timing can change the result
IGF-1 values from different laboratories are not automatically interchangeable because assays differ in calibration, antibody design and how they separate IGF-binding proteins. A borderline result should usually be repeated at the same laboratory before a major diagnostic decision is made.
Modern assays try to neutralize IGF-binding protein interference, yet method-to-method bias persists. A 2020 result of 280 ng/mL and a 2026 result of 280 ng/mL may not represent the same percentile if the laboratory changed platform or reference data; the report footer and historic laboratory name are surprisingly useful clinical details.
Fasting is not routinely required for IGF-1, and morning collection is less critical than for cortisol or testosterone. I still prefer a morning sample after normal food intake when we are resolving a borderline value, because it standardizes the visit and lets us assess glucose, liver markers and other hormones from the same collection.
Kantesti compares the reported interval, units and prior laboratory data so that a numerical jump is not mistaken for biology. When a result changes abruptly, our article on laboratory delta checks explains why sample identity, unit conversion and analytic method should be checked first.
How clinicians confirm or exclude acromegaly
Acromegaly evaluation starts with a repeat age-adjusted IGF-1 and usually uses an oral glucose suppression test only when the result and clinical features support concern. A pituitary MRI is generally performed after biochemical evidence is convincing, not after one slightly high screening result.
During a standard 75-g oral glucose tolerance test, growth hormone should suppress to a very low concentration in people without acromegaly, but the exact cutoff depends on assay sensitivity. IGF-1 above the upper limit plus inadequate suppression gives much stronger evidence than either test alone; pregnancy, diabetes and medication use may affect testing choices.
The reason symptoms matter is that acromegaly has a pattern: progressive ring tightness, jaw change, carpal tunnel syndrome, snoring, sweating, glucose intolerance and colon polyp risk cluster together. One feature alone, such as fatigue or larger shoe size after pregnancy, is common and nonspecific.
Pituitary lesions can also affect prolactin, cortisol and thyroid regulation, so endocrinologists often order a focused panel rather than an indiscriminate scan. Our cortisol and ACTH pattern guide shows why paired hormones are more revealing than a random growth hormone test.
When low IGF-1 prompts an adult growth hormone evaluation
Adult growth hormone deficiency is usually considered when low IGF-1 occurs with known pituitary or hypothalamic disease, prior cranial radiation, head injury or multiple pituitary hormone deficits. In a healthy adult without those risk factors, a low IGF-1 alone has limited diagnostic specificity.
Random growth hormone testing is not useful for diagnosing adult deficiency because secretion is pulsatile. Endocrinologists use dynamic stimulation tests such as insulin tolerance testing, glucagon stimulation or macimorelin in selected patients, with the protocol chosen around seizure history, cardiovascular risk and local expertise.
Symptoms overlap with many common conditions: increased central fat, low exercise capacity, depressed mood and reduced bone density can also reflect sleep deprivation, thyroid disease, iron deficiency or medication effects. A diagnosis should lead to a structured discussion of likely benefits, risks, contraindications and long-term monitoring—not an automatic prescription.
If low IGF-1 comes with low free T4, low sex hormones or unexplained low sodium, the pituitary deserves more focused attention. Our overview of low cortisol warning patterns may help readers understand why adrenal assessment sometimes takes priority.
IGF-1 in children: growth charts matter more than one number
In children, poor height velocity and a downward crossing of growth percentiles are more informative than one low IGF-1 result. A child growing less than about 4 to 5 cm per year before puberty warrants pediatric review, particularly when growth deceleration is persistent.
A low IGF-1 in a child can result from delayed puberty, celiac disease, inflammatory bowel disease, hypothyroidism, low calorie intake or growth hormone deficiency. The 2016 Pediatric Endocrine Society guideline led by Grimberg et al. recommends using growth history, examination and targeted testing rather than diagnosing deficiency from IGF-1 alone.
For a prepubertal child, clinicians typically verify accurate height measurements at least 6 months apart, calculate mid-parental height and review weight trajectory. A child who is short but gaining weight rapidly raises a different set of questions from one who is both short and losing weight.
Kantesti is an AI biomarker interpretation platform that can organize pediatric reports for a clinician, but it cannot replace a growth chart, pubertal examination or pediatric endocrinology assessment. Parents can start with our pediatric thyroid and growth guide when thyroid results accompany the IGF-1 report.
How to repeat IGF-1 and track a meaningful trend
Repeat an unexpected IGF-1 when you are clinically well, using the same laboratory and preferably the same assay. For most non-urgent borderline abnormalities, a repeat after 6 to 12 weeks of stable nutrition, medication use and recovery from acute illness is more useful than an immediate cascade of tests.
Record the date, laboratory, units, reference interval, pregnancy status, cycle or pubertal stage, recent weight change and any oral estrogen or growth hormone use. Those details often explain a 20% swing that looks ominous on a graph but falls within expected analytical and biological variation.
Kantesti helps people compare successive laboratory reports while retaining the original reference ranges and contextual notes. In our analysis of more than 2 million reports, the safest trend interpretation asks whether the same pattern appears across related markers, not whether a single value has changed color.
For a practical way to prepare for follow-up, see our longitudinal testing guide and the details of our clinical validation approach. A trend that is rising across two comparable measurements deserves more attention than a one-off result from a new laboratory.
When to seek endocrine care and what to ask next
Seek timely medical review for high IGF-1 with progressive physical changes, severe headaches or visual symptoms, or for low IGF-1 with known pituitary disease and multiple hormone abnormalities. Sudden visual loss, a severe new headache with vomiting, confusion or fainting needs urgent in-person assessment rather than routine laboratory follow-up.
Bring the full laboratory report, not only the IGF-1 number. Useful questions include: Was this assay age- and sex-adjusted? Should I repeat it at the same laboratory? Could liver disease, food restriction, pregnancy or medication explain it? Do my symptoms justify a dynamic test or endocrinology referral?
As Thomas Klein, MD, I would be cautious about clinics that promise to optimize IGF-1 to a youthful target. Growth hormone treatment is reserved for confirmed conditions and needs specialist monitoring for glucose effects, fluid retention, joint symptoms and, in adults, active malignancy considerations.
Kantesti supports clearer questions for a clinician, but treatment decisions belong with a qualified professional who knows your history. Our Medical Advisory Board helps oversee clinical content, and our guide to a blood test second opinion explains when another review adds value.
Frequently Asked Questions
What is a normal IGF-1 level by age?
Normal IGF-1 varies substantially by age, sex, pubertal stage and laboratory assay. Broadly, puberty can produce values around 100 to 650 ng/mL, while many adults over age 60 have assay-specific intervals closer to roughly 25 to 250 ng/mL. Your own laboratory's reference interval is the valid comparison because two assays can assign different ranges to the same raw number. An IGF-1 z-score between about -2.0 and +2.0 is often used as an age- and sex-adjusted statistical reference, not a diagnosis.
What does a high IGF-1 level mean?
A high IGF-1 level can indicate growth hormone excess, including acromegaly, when it remains above the assay-adjusted upper limit on repeat testing and matches symptoms such as enlarging hands, sweating, headaches or sleep apnea. A mild isolated elevation, especially less than about 15% above the upper limit, can reflect assay variation, puberty, pregnancy or an inappropriate reference range. The Endocrine Society recommends repeat age-normalized IGF-1 and, when appropriate, a 75-g oral glucose suppression test to confirm suspected acromegaly. A single high result does not establish a pituitary diagnosis.
What causes low IGF-1 besides growth hormone deficiency?
Low IGF-1 commonly occurs with calorie restriction, low protein intake, liver disease, uncontrolled diabetes, chronic inflammation, kidney disease and oral estrogen use. The liver produces much of circulating IGF-1, so low albumin, elevated bilirubin or an abnormal INR can point to reduced liver synthesis rather than pituitary failure. In children, delayed puberty, celiac disease and hypothyroidism are frequent alternatives to growth hormone deficiency. Low IGF-1 becomes more concerning when it is below an age-adjusted z-score of -2.0 and occurs with pituitary risk factors or poor growth velocity.
Should I fast before an IGF-1 blood test?
Fasting is usually not required for an IGF-1 test because circulating IGF-1 is relatively stable and reflects growth hormone activity over days to weeks. For a borderline result, many clinicians prefer a morning collection after normal eating and ordinary activity so that glucose, liver markers and other hormones can be compared under consistent conditions. Avoid prolonged fasting, acute illness and major changes in training or diet before a planned repeat when possible. Use the same laboratory for repeat testing because analytic method differences may exceed the effect of fasting.
Can pregnancy raise IGF-1?
Pregnancy can raise maternal IGF-1 later in gestation because placental growth hormone stimulates liver production of IGF-1. Maternal IGF-1 may be lower early in pregnancy and higher in the second and third trimesters, so non-pregnant adult reference intervals are not appropriate. A pregnancy-related elevation does not diagnose acromegaly, although severe headache, visual symptoms or high blood pressure still require prompt obstetric review. A clinician should use a trimester-aware laboratory interpretation whenever available.
Can I improve a low IGF-1 naturally?
A low IGF-1 caused by undernutrition or excessive training may improve after restoring adequate energy intake, protein intake and recovery, often over several weeks rather than days. Many active adults need approximately 1.2 to 1.6 g of protein per kg of body weight daily, but the appropriate intake depends on kidney function, age and total calorie needs. If liver disease, diabetes, thyroid disease or a pituitary disorder is driving the result, diet alone will not correct the underlying problem. Do not use growth hormone, growth-hormone secretagogues or unregulated peptides to raise IGF-1 without specialist care.
Get AI-Powered Blood Test Analysis Today
Join over 2 million users worldwide who trust Kantesti for instant, accurate lab test analysis. Upload your blood test results and receive comprehensive interpretation of 15,000+ biomarkers in seconds.
📚 Referenced Research Publications
Klein, T., Mitchell, S., & Weber, H. (2026). Kantesti Ltd. (2026). Urobilinogen in Urine Test: Complete Urinalysis Guide 2026. Zenodo. https://doi.org/10.5281/zenodo.18226379. Kantesti AI Medical Research.
Klein, T., Mitchell, S., & Weber, H. (2026). Kantesti Ltd. (2026). Iron Studies Guide: TIBC, Iron Saturation & Binding Capacity. Zenodo. https://doi.org/10.5281/zenodo.18248745. Kantesti AI Medical Research.
📖 External Medical References
⚕️ Medical Disclaimer
This article is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider for diagnosis and treatment decisions.
E-E-A-T Trust Signals
Experience
Physician-led clinical review of lab interpretation workflows.
Expertise
Laboratory medicine focus on how biomarkers behave in clinical context.
Authoritativeness
Written by Dr. Thomas Klein with review by Dr. Sarah Mitchell and Prof. Dr. Hans Weber.
Trustworthiness
Evidence-based interpretation with clear follow-up pathways to reduce alarm.